Sökning: WFRF:(De Wit Ronald) >
Effect of docetaxel...
Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14)
-
- Josefsson, Andreas, 1979- (författare)
- Umeå University,Umeå universitet,Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM),Urologi och andrologi,Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
-
- Jellvert, Åsa (författare)
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Region Västra Götaland, NU Hospital Group, Department of Surgery, Uddevalla, Sweden; Department of Oncology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden
-
- Holmberg, Erik (författare)
- Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Regional Cancer Centre West, Gothenburg, Sweden,Regional Cancer Center Western Sweden
-
visa fler...
-
- Brasso, Klaus (författare)
- Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark,Copenhagen University Hospital
-
- Meidahl Petersen, Peter (författare)
- Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark,Copenhagen University Hospital
-
- Aaltomaa, Sirpa (författare)
- Department of Urology, Kuopio University Hospital, Kuopio, Finland
-
- Luukkaa, Marjaana (författare)
- Department of Oncology, Turku University Hospital, Turku, Finland
-
- Verhagen, Paul (författare)
- Department of Urology, Erasmus Medical Centre, Rotterdam, Netherlands,Erasmus University Medical Center
-
- de Wit, Ronald (författare)
- Department of Medical Oncology, Erasmus University Medical Centre Cancer Institute, Rotterdam, Netherlands
-
- Ahlgren, Göran (författare)
- Lund University,Lunds universitet,Urologisk cancerforskning, Malmö,Forskargrupper vid Lunds universitet,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Urological cancer, Malmö,Lund University Research Groups,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital
-
- Andrén, Ove (författare)
- Örebro University
-
- Castellanos, Enrique (författare)
- Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
-
- Seke, Mihalj (författare)
- Centrallasarettet Växjö, Växjö, Sweden
-
- Widmark, Anders (författare)
- Umeå University,Umeå universitet,Institutionen för strålningsvetenskaper
-
- Damber, Jan-Erik (författare)
- Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
-
visa färre...
-
(creator_code:org_t)
-
- Taylor & Francis, 2023
- 2023
- Engelska.
-
Ingår i: Acta Oncologica. - : Taylor & Francis. - 0284-186X .- 1651-226X. ; 62:4, s. 372-380
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
http://dx.doi.org/10... (free)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Historically, endocrine therapy was used in a range of scenarios in patients with rising PSA, both as a treatment for locally advanced non-metastatic prostate cancer and PSA recurrence following curative intended therapy. In the present study the objective was to investigate if chemotherapy added to endocrine therapy could improve progression-free survival (PFS).Materials and Methods: Patients with hormone-naïve, non-metastatic prostate cancer and rising prostate-specific antigen (PSA), enrolled from Sweden, Denmark, the Netherlands, and Finland, were randomized to long-term bicalutamide (150 mg daily) or plus docetaxel (75 mg/m2, q3w, 8–10 cycles) without prednisone, after stratification for the site, prior local therapy or not, and PSA doubling time. The primary endpoint was 5-year PFS analyzed with a stratified Cox proportional hazards regression model on intention to treat basis.Results: Between 2009 and 2018, a total of 348 patients were randomized; 315 patients had PSA relapse after radical treatment, 33 patients had no prior local therapy. Median follow-up was 4.9 years (IQR 4.0–5.1). Adding docetaxel improved PFS (HR 0.68, 95% CI 0.50–0.93; p = 0.015). Docetaxel showed an advantage for patients with PSA relapse after prior local therapy (HR 0.67, 95% CI 0.49–0.94; p = 0.019). One event of neutropenic infection/fever occurred in 27% of the patients receiving docetaxel. Limitations were slow recruitment, lack of enrolling patients without radical local treatment, and too short follow-up for evaluation of overall survival in patients with PSA relapse.Conclusion: Docetaxel improved PFS in patients starting bicalutamide due to PSA relapse after local therapy or localized disease without local therapy. Confirmatory studies of the efficacy of docetaxel in the setting of PSA-only relapse in addition to endocrine therapies may be justified if longer follow-up will show increased metastatic-free survival.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
Nyckelord
- bicalutamide
- docetaxel
- Prostate cancer
- psa relapse
- randomized clinical trial
- bicalutamide
- docetaxel
- Prostate cancer
- psa relapse
- randomized clinical trial
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Josefsson, Andre ...
-
Jellvert, Åsa
-
Holmberg, Erik
-
Brasso, Klaus
-
Meidahl Petersen ...
-
Aaltomaa, Sirpa
-
visa fler...
-
Luukkaa, Marjaan ...
-
Verhagen, Paul
-
de Wit, Ronald
-
Ahlgren, Göran
-
Andrén, Ove
-
Castellanos, Enr ...
-
Seke, Mihalj
-
Widmark, Anders
-
Damber, Jan-Erik
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Urologi och njur ...
- Artiklar i publikationen
-
Acta Oncologica
- Av lärosätet
-
Umeå universitet
-
Lunds universitet